Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data.

The bioavailability after oral administration of (S)-(-)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro [4,5] decane-L-tartarate monohydrate (YM796), which is being developed as an antidementia drug, at a dose of 1 mg/kg was very low (3.4%) in rats, but considerably higher (16.1%) in dogs. The oral clearances (CLoral, Dose/AUCoral) in rats and dogs were, respectively, 300 and 18 times more than that already reported in humans. We have previously reported successful attempts to predict the in vivo hepatic metabolic clearance of YM796 from in vitro data in humans. In our study, the in vitro metabolism of YM796 was determined using liver microsomes prepared from both rats and dogs and we also investigated if the species difference observed in vivo could be quantitatively reproduced in vitro. In rats, total metabolite formation could be described by single component kinetics with a Km of 13.4 microM and a Vmax of 520 nmol/min/g liver. However, in dogs, total metabolite formation could be described by three components, as also reported for humans. The Km and Vmax values for the high-affinity, low-capacity component (Km1 and Vmax1) in dogs and humans were, respectively, 8.1 and 1.7 microM, and 10.9 and 1.2 nmol/min/g liver. The overall intrinsic metabolic clearances estimated from the in vitro studies (CLint,in vitro) for rats and dogs were 38.8 and 2.6 ml/min/g liver, respectively, being approximately 40 and 3 times more than that previously reported for humans (0.94 ml/min/g liver). The overall intrinsic hepatic clearances (CLint,in vivo) calculated from in vivo CLoral were 30.4, 3.4 and 0.73 ml/min/g liver for rats, dogs and humans, respectively, indicating that the in vivo hepatic clearance of YM796 can be predicted from in vitro metabolism data in each species. Thus, the pronounced species difference in the metabolic clearance observed in vivo can be quantitatively predicted from in vitro metabolic data using liver microsomes, and was predominantly due to the large difference in the Vmax values.

[1]  M Rowland,et al.  Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.

[2]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[3]  J. Cannon,et al.  Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. , 1973, Biochemical pharmacology.

[4]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[5]  M. Bayliss,et al.  Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. , 1990, Biochemical Society transactions.

[6]  U. Klotz,et al.  Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.

[7]  R. Roberts,et al.  Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man , 1975, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[9]  G R Wilkinson,et al.  Clearance approaches in pharmacology. , 1987, Pharmacological reviews.

[10]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[11]  L. Benet,et al.  The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine , 1995, Clinical pharmacology and therapeutics.

[12]  M. Grant,et al.  Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. , 1987, Biochemical pharmacology.

[13]  L. Benet,et al.  Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.

[14]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[15]  Y. Sugiyama,et al.  Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.

[16]  G R Wilkinson,et al.  Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. , 1977, The Journal of pharmacology and experimental therapeutics.

[17]  M. Rowland,et al.  Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model , 1986, The Journal of pharmacy and pharmacology.

[18]  S. Orrenius,et al.  The isolation of rat intestinal microsomes with stable cytochrome P-450 and their metabolism of benzo(alpha) pyrene. , 1976, Archives of biochemistry and biophysics.

[19]  H. Akaike.  Fitting autoregressive models for prediction , 1969 .

[20]  Y. Sugiyama,et al.  Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. , 1995, Toxicology letters.

[21]  O. Raabe,et al.  Development of in vitro Vmax and Km values for the metabolism of isofenphos by P-450 liver enzymes in animals and human. , 1993, Toxicology and Applied Pharmacology.

[22]  R. Chenery,et al.  Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. , 1989, Biochemical pharmacology.

[23]  P. Beaune,et al.  Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.

[24]  Yuichi Sugiyama,et al.  Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtainedin vitro as well as on physiological data , 1982, Journal of pharmacokinetics and biopharmaceutics.

[25]  K. Yamaoka,et al.  Local Absorption Kinetics of Levofloxacin from Intestinal Tract into Portal Vein in Conscious Rat Using Portal-Venous Concentration Difference , 1996, Pharmaceutical Research.

[26]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[27]  L. Kaminsky,et al.  Small intestinal cytochromes P450. , 1991, Critical reviews in toxicology.

[28]  Y. Sugiyama,et al.  Prediction of the disposition ofβ-lactam antibiotics in humans from pharmacokinetic parameters in animals , 1984, Journal of Pharmacokinetics and Biopharmaceutics.